Eli Lilly on Thursday reported third-quarter earnings and income that topped estimates and hiked its full-year outlook, as the corporate continued to see sturdy demand for its blockbuster weight reduction drug Zepbound and diabetes therapy Mounjaro.

Shares of the corporate closed greater than 3% larger Thursday.

The pharmaceutical large now expects its fiscal 2025 income to come back in between $63 billion and $63.5 billion, up from previous guidance of $60 to $62 billion. Eli Lilly additionally expects full-year adjusted revenue to come back in between $23 and $23.70 per share, rising from its earlier outlook of $21.75 to $23 a share.

Eli Lilly mentioned the steering displays President Donald Trump‘s present tariffs as of Thursday, however doesn’t embrace his threatened levies on prescribed drugs imported into the U.S.

Mounjaro raked in $6.52 billion in income for the quarter, up 109% from the identical interval a yr in the past. That blew previous the $5.51 billion that analysts have been anticipating, in line with StreetAccount. 

Zepbound, which entered the market roughly two years in the past, posted $3.59 billion in income for the third quarter. That is up 184% from the year-earlier interval and barely forward of the $3.5 billion that Wall Road was anticipating, in line with StreetAccount estimates.

In an interview with CNBC on Thursday, Eli Lilly CEO Dave Ricks mentioned the “actual star right here” of the quarter is tirzepatide, the lively ingredient in Zepbound and Mounjaro. Each medicine are main the U.S. marketplace for weight problems and diabetes, he mentioned. 

Ricks mentioned the quarterly beat was pushed by “actually sturdy worldwide efficiency,” pointing to Mounjaro’s launch in China, Brazil and India earlier this yr. 

“What we’re seeing is a world demand for this product,” he advised CNBC’s “Squawk on the Street.”

On an earnings name Thursday, Ricks mentioned Eli Lilly gained share within the injectable weight problems and diabetes marketplace for the fifth consecutive quarter. The corporate’s medicine account for practically 6 out of 10 prescriptions inside that class of medicines.

This is what Eli Lilly reported for the third quarter in contrast with what Wall Road was anticipating, based mostly on a survey of analysts by LSEG: 

• Earnings per share: $7.02 adjusted vs. $5.69 anticipated
• Income: $17.60 billion vs. $16.01 billion anticipated

The outcomes come as Eli Lilly works to take care of its edge over chief rival Novo Nordisk within the booming marketplace for a category of weight problems and diabetes medicine referred to as GLP-1s.

The corporate posted third-quarter income of $17.60 billion, up 54% from the identical interval a yr in the past. 

Gross sales within the U.S. jumped 45% to $11.30 billion. Eli Lilly mentioned that was pushed by a 60% enhance in quantity — or the variety of prescriptions or items bought — for its merchandise, primarily for Mounjaro and Zepbound. That was partially offset by decrease realized costs of the medicine, the corporate mentioned.

The pharmaceutical large booked internet revenue of $5.58 billion, or $6.21 per share, for the third quarter. That compares with internet revenue of $970.3 million, or $1.07 per share, a yr earlier. 

Excluding one-time gadgets related to the worth of intangible belongings and different changes, Eli Lilly posted earnings of $7.02 per share for the second quarter.

The outcomes underscore Eli Lilly’s sturdy benefit within the booming GLP-1 drug market.

The corporate has gained the bulk market share over the past yr, because of the sturdy profile of its weight reduction and diabetes injections and a lift from its direct-to-consumer gross sales, amongst different efforts. Eli Lilly took one other stride to spice up entry to Zepbound on Wednesday, partnering with Walmart to offer in-store pickup of discounted vials of the drug for cash-paying sufferers.

Within the interview, Ricks mentioned Eli Lilly plans to broaden its direct-to-consumer and cash-pay choices for its medicine.

The corporate is now betting on its intently watched experimental weight problems tablet, orforglipron, to solidify its dominance within the area, particularly as Novo Nordisk and different drugmakers race to convey their very own capsules or next-generation injections to the market. 

“We have been ramping each manufacturing and planning for actually a broad international rollout upon regulatory approval,” Ricks advised CNBC, referring to orforglipron’s launch.

On Thursday, Novo Nordisk launched a rival bid for U.S. weight problems biotech firm Metsera, hijacking a suggestion from Pfizer because it races to catch as much as Eli Lilly.

When requested about competitors, Ricks mentioned on the earnings name that “in fact, everyone wish to be in our place, however we’re targeted on defending it and principally simply executing the play we’ve got.”